Compare Cytokinetics Inc (CYTK) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs 3M Company — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while 3M Company trades at $163.61 (market cap $83.61B). The key difference: 3M Company is far larger — about 9.8× Cytokinetics Inc's market cap, and 3M Company pays a 1.92% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and 3M Company for 169 Days on average.
| CYTK | MMM | |
|---|---|---|
Market Cap | $8.50B | $83.61B |
Volume | 2,395,556 | 3,188,723 |
Sector | Health | Industrials |
52-Week High | $87.26 | $183.79 |
52-Week Low | $54.76 | $141.10 |
Typical Hold Time | 19 Days | 169 Days |
Enterprise Value | $8.60B | $92.83B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
3M (MMM) trades at $163.57, showing minimal daily movement (-0.04%) amid a bearish technical outlook. The company demonstrates strong profitability with 11.9% net margins and impressive ROE of 82.77%, though revenue has declined from 2022 peaks. Recent Q2 2026 earnings beat expectations with 5.4% organic growth, supporting management's turnaround narrative. Analyst sentiment is evenly split between Buy and Hold ratings with a $191 consensus target representing 17% upside potential.
The stock presents a value opportunity with manageable litigation risks, but faces headwinds from weak consumer demand and high debt levels. Near-term catalysts include continued operational improvements and data-center expansion, while risks center on execution of margin targets and macroeconomic pressures on industrial markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
